Literature DB >> 9306577

Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide.

C Sakakura1, E A Sweeney, T Shirahama, Y Igarashi, S Hakomori, H Tsujimoto, T Imanishi, M Ogaki, T Ohyama, J Yamazaki, A Hagiwara, T Yamaguchi, K Sawai, T Takahashi.   

Abstract

Bax, one of the bcl-2 family genes, is expressed in a number of untransformed cell lines and various breast tissues, whereas only weak or no expression has been detected in breast cancer cell lines and malignant breast tissue. Human breast cancer MCF-7 cells, which have a weak bax gene expression, were stably transfected with pCX2neo bax, encoding human bax; and two unique clones, MCF-7/bax-1 and MCF-7/ bax-2, that expressed different levels of bax were generated. Sensitivity to cisplatin (CDDP) and etoposide (VP-16) was examined and each stable transfectant was more sensitive to these agents than the parental MCF-7 cells. The degree of enhancement in sensitivity to these anticancer agents was dependent on the expression level of bax. The enzyme-linked immunosorbent assay (ELISA), which quantifies DNA damage, demonstrated that this sensitization was due to apoptosis. Thus, we suggest that exogenous bax-alpha overexpression may be one of the factors determining cellular chemosensitivity in MCF-7 breast cancer cells and that it could be applied therapeutically to enhance chemosensitivity in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306577     DOI: 10.1007/BF02388231

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

1.  The Bcl-2 family of proteins: regulators of cell death and survival.

Authors:  G Nuñez; M F Clarke
Journal:  Trends Cell Biol       Date:  1994-11       Impact factor: 20.808

2.  Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.

Authors:  V N Sumantran; M W Ealovega; G Nuñez; M F Clarke; M S Wicha
Journal:  Cancer Res       Date:  1995-06-15       Impact factor: 12.701

3.  bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair.

Authors:  S Kamesaki; H Kamesaki; T J Jorgensen; A Tanizawa; Y Pommier; J Cossman
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

4.  Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis.

Authors:  Q Zhan; S Fan; I Bae; C Guillouf; D A Liebermann; P M O'Connor; A J Fornace
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

5.  Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.

Authors:  M Dole; G Nuñez; A K Merchant; J Maybaum; C K Rode; C A Bloch; V P Castle
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

6.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

7.  Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.

Authors:  R C Bargou; P T Daniel; M Y Mapara; K Bommert; C Wagener; B Kallinich; H D Royer; B Dörken
Journal:  Int J Cancer       Date:  1995-03-16       Impact factor: 7.396

8.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

9.  Bcl-2 blocks p53-dependent apoptosis.

Authors:  S K Chiou; L Rao; E White
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

10.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

Authors:  R Silvestrini; S Veneroni; M G Daidone; E Benini; P Boracchi; M Mezzetti; G Di Fronzo; F Rilke; U Veronesi
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  6 in total

Review 1.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

2.  Reduced expression of Bax in small cell lung cancer cells is not sufficient to induce cisplatin-resistance.

Authors:  J Biagosch; R M Huber; Albrecht Bergner
Journal:  Eur J Med Res       Date:  2010-10-25       Impact factor: 2.175

Review 3.  The mitochondrial death pathway: a promising therapeutic target in diseases.

Authors:  Sanjeev Gupta; George E N Kass; Eva Szegezdi; Bertrand Joseph
Journal:  J Cell Mol Med       Date:  2009-02-09       Impact factor: 5.310

4.  Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARβ2 and RASSF1A demethylation.

Authors:  Kehan Li; Jianxue Yang; Xuechang Han
Journal:  Int J Mol Sci       Date:  2014-12-17       Impact factor: 5.923

5.  Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance.

Authors:  Justin Kale; Ozgur Kutuk; Glauber Costa Brito; Tallulah S Andrews; Brian Leber; Anthony Letai; David W Andrews
Journal:  EMBO Rep       Date:  2018-07-09       Impact factor: 8.807

6.  Integrated microfluidic single-cell immunoblotting chip enables high-throughput isolation, enrichment and direct protein analysis of circulating tumor cells.

Authors:  Aynur Abdulla; Ting Zhang; Shanhe Li; Wenke Guo; Antony R Warden; Yufang Xin; Nokuzola Maboyi; Jiatao Lou; Haiyang Xie; Xianting Ding
Journal:  Microsyst Nanoeng       Date:  2022-02-02       Impact factor: 7.127

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.